MedTrace Logo

Combination Therapy With GEN0101 and Pembrolizmub in Advanced Melanoma Patients PIb/PII

NCT03818893 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2019-01-30

No results posted yet for this study

Summary

This is a multi-center, open-labeled, non-randomized, single arm investigator-initiated trial to evaluate the safety and efficacy of GEN0101 and Pembrolizmub combination in patients with advanced melanoma.

Conditions

Interventions

DRUG

Combination of GEN0101 and Pembrolizmub

New Combination immunotherapy GEN0101 and Pembrolizmub

Sponsors & Collaborators

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • ISHIHARA SANGYO KAISHA,LTD. Japan

    collaborator UNKNOWN

  • Osaka University

    lead OTHER

Principal Investigators

  • Atsushi Tanemura, Lecture · Osaka University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-31
Primary Completion
2021-12-31
Completion
2022-06-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03818893 on ClinicalTrials.gov